Education
About Us
Working with TipRanks
Follow Us
Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
RESEARCH TOOLSreports
IBX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
Volume347.18K
Average Volume (3M)7.32M
Market Cap
AU$2.82M
Enterprise ValueAU$3.80M
Total Cash (Recent Filing)AU$2.67M
Total Debt (Recent Filing)AU$2.85M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding201,341,420
10 Day Avg. Volume21,107,499
30 Day Avg. Volume7,324,785
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.35
Price to Sales (P/S)0.00
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Imagion Biosystems Ltd. News
PremiumCompany Announcements
Imagion Biosystems Announces Director’s Acquisition of Unlisted Options
PremiumCompany Announcements
Imagion Biosystems Issues New Employee Incentive Securities
PremiumCompany Announcements
Imagion Biosystems Advances HER2 Breast Cancer Trial with FDA Support
PremiumCompany Announcements
Imagion Biosystems to Present at Landmark Venture Forum
PremiumCompany Announcements
Imagion Biosystems Relocates Office to Enhance Operations
PremiumCompany Announcements
Imagion Biosystems Ltd. AGM Results: All Resolutions Carried
PremiumCompany Announcements
Imagion Biosystems Advances Cancer Detection ProgramsOptions Prices
Currently, No data available
---
Ownership Overview
3.07% Insiders
―
Mutual Funds
― Other Institutional Investors
96.93% Public Companies and
Individual Investors
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.08 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$2.82M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 42 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Currently, no data Available
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 201,341,420 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:IBX Sentiment 63%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.87%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Wellfully Limited
―
Inoviq Ltd
―